122 related articles for article (PubMed ID: 11287119)
1. Three mutations in v-Rel render it resistant to cleavage by cell-death protease caspase-3.
Barkett M; Dooher JE; Lemonnier L; Simmons L; Scarpati JN; Wang Y; Gilmore TD
Biochim Biophys Acta; 2001 Apr; 1526(1):25-36. PubMed ID: 11287119
[TBL] [Abstract][Full Text] [Related]
2. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2003 Oct; 22(44):6928-36. PubMed ID: 14534540
[TBL] [Abstract][Full Text] [Related]
3. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
4. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
Fan Y; Gélinas C
Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 and CrmA have different effects on transformation, apoptosis and the stability of I kappa B-alpha in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins.
White DW; Gilmore TD
Oncogene; 1996 Sep; 13(5):891-9. PubMed ID: 8806678
[TBL] [Abstract][Full Text] [Related]
6. In vivo evolution of c-rel oncogenic potential.
Hrdlicková R; Nehyba J; Humphries EH
J Virol; 1994 Apr; 68(4):2371-82. PubMed ID: 8139023
[TBL] [Abstract][Full Text] [Related]
7. A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel.
Mosialos G; Hamer P; Capobianco AJ; Laursen RA; Gilmore TD
Mol Cell Biol; 1991 Dec; 11(12):5867-77. PubMed ID: 1944267
[TBL] [Abstract][Full Text] [Related]
8. Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein.
Chen C; Agnès F; Gélinas C
Mol Cell Biol; 1999 Jan; 19(1):307-16. PubMed ID: 9858554
[TBL] [Abstract][Full Text] [Related]
9. The v-Rel oncoprotein blocks apoptosis and proteolysis of I kappa B-alpha in transformed chicken spleen cells.
White DW; Roy A; Gilmore TD
Oncogene; 1995 Mar; 10(5):857-68. PubMed ID: 7898928
[TBL] [Abstract][Full Text] [Related]
10. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
Morrison LE; Boehmelt G; Enrietto PJ
Oncogene; 1992 Jun; 7(6):1137-47. PubMed ID: 1594245
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo.
White DW; Pitoc GA; Gilmore TD
Mol Cell Biol; 1996 Mar; 16(3):1169-78. PubMed ID: 8622661
[TBL] [Abstract][Full Text] [Related]
13. Discreet mutations from c-Rel to v-Rel alter kappaB DNA recognition, IkappaBalpha binding, and dimerization: implications for v-Rel oncogenicity.
Phelps CB; Ghosh G
Oncogene; 2004 Feb; 23(6):1229-38. PubMed ID: 14961076
[TBL] [Abstract][Full Text] [Related]
14. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
Mosialos G; Gilmore TD
Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.
Rayet B; Fan Y; Gélinas C
Mol Cell Biol; 2003 Mar; 23(5):1520-33. PubMed ID: 12588973
[TBL] [Abstract][Full Text] [Related]
16. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
Epinat JC; Dvorin EL; Gilmore TD
Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
[TBL] [Abstract][Full Text] [Related]
17. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
Fan Y; Rayet B; Gélinas C
Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
[TBL] [Abstract][Full Text] [Related]
18. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
Starczynowski DT; Trautmann H; Pott C; Harder L; Arnold N; Africa JA; Leeman JR; Siebert R; Gilmore TD
Oncogene; 2007 Apr; 26(19):2685-94. PubMed ID: 17072339
[TBL] [Abstract][Full Text] [Related]
19. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
Gilmore TD
Oncogene; 1999 Nov; 18(49):6925-37. PubMed ID: 10602467
[TBL] [Abstract][Full Text] [Related]
20. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts.
Sif S; Capobianco AJ; Gilmore TD
Oncogene; 1993 Sep; 8(9):2501-9. PubMed ID: 8361761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
